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Characterization of hepatic tumors using
[11C]metomidate through positron emission
tomography: comparison with [11C]acetate
Anne Roivainen1, Alexandru Naum1,2, Heikki Nuutinen3, Rauli Leino4, Heimo Nurmi4, Kjell Någren1,7, Riitta Parkkola4,
Johanna Virtanen4, Markku Kallajoki5, Harry Kujari5, Jari Ovaska6, Peter Roberts6 and Marko Seppänen1*
Abstract
Background: Using positron emission tomography (PET), we compared two tracers, [11C]metomidate ([11C]MTO)
and [11C]acetate ([11C]ACE), for the characterization of hepatic tumors.
Methods: Thirty-three patients underwent PET with [11C]MTO and [11C]ACE and magnetic resonance imaging (MRI).
Based on the histology of the tumor biopsy, 14 patients had hepatocellular carcinoma (HCC), 9 patients had focal
nodular hyperplasia (FNH), and 10 patients had other types of hepatic tumors. Tumor uptake was evaluated by
calculating the maximum and mean standardized uptake value and tumor-to-liver ratio.
Results: Altogether, 120 hepatic lesions (59 HCC, 18 FNH, 30 metastases of different primaries, 9 adenomas, and 4
regenerating nodules of liver cirrhosis) were detected by MRI. The overall tumor detection rate was slightly higher
for [11C]MTO (39%) than for [11C]ACE (33%). [11C]ACE was more sensitive for HCC detection (50% versus 43%,
respectively), whereas [11C]MTO was more sensitive for FNH detection (78% versus 44%, respectively). In HCC
patients, the tumor grade correlated with [11C]ACE, but not with [11C]MTO. All of the patients with liver metastases,
from various primary tumors (n = 10), were negative for both tracers.
Conclusions: Due to low sensitivity, [11C]MTO and [11C]ACE PET have only limited value in diagnosing hepatic
tumors.
Keywords: [11C]acetate, Focal nodular hyperplasia, Hepatocellular carcinoma, Metastases, [11C]metomidate, Positron
emission tomography
Background
Diagnostic assessment of primary liver tumors and metas-
tases by various imaging modalities remains challenging.
The challenge is in distinguishing between benign and
malignant lesions, and often, a histopathological examin-
ation of a biopsy specimen is required for a definite diag-
nosis [1,2]. Noninvasive anatomic imaging modalities,
including computed tomography (CT), magnetic reson-
ance imaging (MRI), as well as ultrasound (US), are com-
monly used for the detection and characterization of
intrahepatic processes [3-5]. Dynamic contrast-enhanced
MRI facilitates the characterization of some liver tumors,
for example, hemangioma, focal nodular hyperplasia
(FNH), and typical hepatocellular carcinoma (HCC). How-
ever, the fundamental limitation of anatomical imaging, in
general, is the limited capability of detecting malignant
hepatic tumors [6,7].
In liver imaging, 2-[18F]-fluoro-2-deoxy-D-glucose
([18F]FDG) positron emission tomography (PET)/CT
was proven to be highly sensitive in detecting hepatic me-
tastases of different primary tumors and distant tumor
spread [8-10]. However, the performance of [18F]FDG PET
imaging in the detection of HCC is not optimal because of
the variable tracer uptake which depends on tumor differ-
entiation. PET with [11C]acetate ([11C]ACE) could serve as
an alternative for the detection of HCC lesions, and the
results by other authors have revealed high sensitivity and
specificity for HCC [11-13]. In addition, [11C]ACE PET
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detects prostate cancer effectively [14,15]. Intravenously
injected [11C]ACE enters the Krebs cycle as a substrate for
β-oxidation in fatty acid synthesis and cholesterol synthe-
sis. Fatty acid synthesis may be the major reason for the
uptake of [11C]ACE by hepatic tumors [16].
Besides [11C]ACE, radiolabeled choline tracers
([11C]choline, [18F]fluorocholine) have also revealed high
sensitivity for the diagnosis of HCC as well [17,18].
[18F]fluorocholine has been registered in several EU
countries in this indication. However, the combination
of two tracers, for example [18F]FDG and [11C]ACE or
[18F]FDG and [18F]fluorocholine, improves the detection
and staging of HCC especially [18,19]. Nevertheless, an
ideal PET tracer capable of detecting all liver lesions
does not exist, and thus, there is still room for the evalu-
ation of other PET tracers in patients with HCC.
Metomidate (methyl derivative of etomidate) binds
to gamma-aminobutyric acid (GABA) receptors and
inhibits 11β-hydroxylase (CYP11B1, P45011β), an en-
zyme essential in the biosynthesis of aldosterone and
cortisol. [11C]metomidate ([11C]MTO) was a PET tracer
for the imaging of adrenocortical tumors [20,21]. The
GABA receptor is upregulated in HCC, and it may be a
potential target for [11C]MTO, which would promote
[11C]MTO as a useful marker for HCC [22].
In this study, we tested the hypothesis if PET imaging
with [11C]MTO could detect hepatic tumors. Accord-
ingly, we examined [11C]MTO PET in patients with
HCC, FNH, and other types of hepatic tumors in com-
parison with [11C]ACE PET imaging.
Methods
Subjects
This prospective study involved 33 patients (19 males
and 14 females with mean age of 55 years, ranging from
16 to 77 years) with detected liver masses (CT/MRI/US)
or metastases together with a known primary tumor.
The study was carried out at Turku University Hospital,
Turku, Finland. The patients had not been operated on
or received any oncological treatment prior to inclusion.
The study was conducted according to the guidelines of
the Declaration of Helsinki, and the study protocol was
approved by the Joint Commission of Ethics of Turku
University Hospital. Each subject gave their written
informed consent after the purpose, nature, and possible
risks of the study had been explained to them.
The histological diagnosis was based on a percutan-
eous needle biopsy and/or surgical resection, except for
five typical FNH lesions that were characterized and
followed up by MRI. Of the 33 patients, 14 had HCC (one
highly, nine moderately, and four poorly differentiated), 9
patients had FNH, 6 patients had liver metastases
(four of colon carcinoma, one of a carcinoid tumor,
and one of unknown origin), 2 patients had
regenerating nodules of liver cirrhosis, 1 patient had
cholangiocarcinoma, and 1 patient had hepatocellular
adenoma. The patients were divided into the
following groups according to the histology of the
primary tumor: group I (14 patients with HCC),
group II (9 patients with FNH), and group III (10
patients with other types of liver tumors).
Magnetic resonance imaging
MR imaging was done on a 1.5 T scanner (Gyroscan
Intera CV Nova Dual, Philips Medical Systems, Best,
The Netherlands) using a sensitivity encoding body coil.
The patients underwent a dynamic contrast-enhanced
MRI, and this was used as the gold standard for
measurement.
The MRI procedure consisted of coronal and axial
balanced fast field echo sequences (echo time (TE) =
1.39 to 1.77 ms, repetition time (TR) = 2.78 to 4.12 ms,
flip angle = 60°, and matrix = 224), T2-weighted axial fat
saturation sequence (TE = 70 ms, TR = 1600 ms, flip
angle = 90°, and matrix = 256), and T1-weighted axial
in-opp and coronal in-phase sequences (TE = 2.3 and
4.6 ms, TR = 178 to 179 ms in axial and TR = 206 to
207 ms in coronal plane, flip angle = 80°, and matrix =
192). All sequences were scanned with 355- to 440-mm
field of view and 7-mm slice thickness. T1-weighted cor-
onal and axial sequences were repeated with intravenous
gadolinium. The latter included 20, 60, and 180 s of
dynamic contrast-enhanced imaging.
PET scanning
All PET examinations were performed after an over-
night fast. The production of positron-emitting tracers
[11C]MTO and [11C]ACE has been described previously
elsewhere [21,23]. An antecubital venous catheter was
inserted in the right arm for the injection of tracers.
PET imaging was performed either on a GE Advance
PET (General Electric Medical Systems, Milwaukee, WI,
USA; 11 patients) or an ECAT HR+ (Siemens/CTI, Knox-
ville, TN, USA; 22 patients) scanner with the patient in a
supine position. All patients were studied with both
tracers. For 11 patients, the [11C]MTO and [11C]ACE PET
were done on the same day; for 13 patients, within 24 h;
and for 10 patients, within 2 weeks. After the completion
of a transmission scan (5 min using an externally rotating
68Ge/Ga rod), the subjects were given an intravenous bolus
of 646 ± 108 MBq of [11C]MTO or 672 ± 73 MBq of
[11C]ACE. A dynamic scan of the hepatic region, lasting
25 min (6 × 60 s, 3 × 180 s, and 2 × 300 s), was done to
assess the radioactivity concentration as a function of time
of the liver hotspots on the axial field of view. Following
the dynamic acquisition, static emission images were
acquired (25 to 45 min), covering the area from the level
of the clavicle and moving down to the pelvic floor
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(2D mode, four to five bed positions, 5 min each). After
the emission scanning, a 2-min transmission scan was
performed at each table position.
All the data were corrected for dead time, radio-
active decay, and photon attenuation. PET images
were reconstructed using ordered-subset expectation
maximization reconstruction algorithm and displayed in a
128 × 128 matrix, 35 or 47 transverse slices with a slice
thickness of 4.5 mm. The final in-plane resolution in the
reconstructed and Hann-filtered images was approxi-
mately 5 mm at 10 cm from the center of the gantry.
MR image analysis
An image analysis of the MRI scans was performed in
order to detect and locate the liver tumors accurately.
The number and size of the lesions were measured. MRI
analysis was also used to characterize the tumors prior
to the final histological examination. Five out of nine
FNH lesions were characterized and monitored by MRI.
The MR images were analyzed by an experienced senior
radiologist.
PET image analysis
All PET images were reviewed on a computer screen in
the transaxial, coronal, and sagittal planes along with
maximum-intensity projection images. Two experienced
reporters evaluated independently the tracers’ uptake
both visually and semi-quantitatively. The degree of
radiotracer uptake in the tumor was visually scored by
comparing the apparent tumor to the surrounding liver
parenchymal uptake as negative (i.e., less-than-liver or
equivalent-to-liver uptake) or positive (i.e., higher-than
-liver uptake). In case of discrepancies between the two
reviewers, a joint reading was held to reach a consensus.
All PET images were fused with the corresponding
MR images to ensure an accurate anatomic identification
of the tumor. For a semi-quantitative analysis, a 15-mm
circular region of interest (ROI) was drawn on three
consecutive transaxial image planes covering the tumor.
The maximum standardized uptake value (SUVmax) and
the mean SUV (SUVmean) of the lesion were calculated
from the maximum/mean radioactivity concentration of
the tumor ROIs between 25 to 45 min after injection.
An ROI of the same size was used to evaluate the SUVs
of the adjacent normal liver tissue in the same patient,
and the tumor-to-liver (T/L) ratio was calculated by div-
iding the tumor SUV by the liver SUV. For patients who
showed little or no lesion-related tracer uptake, the ROI
was placed at the anatomical position of the lesion
depicted on MR using direct visual alignment of both
sets of images. If more than one lesion were positive, the
lesion which showed the most intense uptake was
chosen as representative of all lesions.
Statistical analyses
Results are expressed as mean ± standard deviation
(SD). Analysis of variance was used to compare the
SUVmax, SUVmean, and the T/L ratio among the three
study groups. The SUVmax and SUVmean parameters in
tumors showing radiotracer uptake and those with no
uptake were compared using an unpaired t test.
Correlations between HCC grade and tumor SUVmax
or SUVmean were calculated using Spearman’s rank cor-
relation test. All statistical tests were performed with the
SAS statistical analysis system (Enterprise Guide, version
2.0, SAS Institute Inc., Cary, NC, USA). A P value <0.05
was considered statistically significant.
Results
MRI findings
Altogether, 120 hepatic lesions (59 HCC, 18 FNH, 30
metastases of different primaries, 9 adenomas, and 4 re-
generating nodules of liver cirrhosis) were detected by
MRI. In group I, 2 patients had a unifocal tumor, and 12
had multifocal tumors. The mean tumor size of the lar-
gest lesion detected by MRI in each patient was 10.6 cm
(range 3 to 19 cm). In group II, four patients had
unifocal tumors, and multifocal tumors were in five
patients; the mean tumor size of the largest FNH lesion
was 4.8 cm (range 1.5 to 9.5 cm). In group III, nine
patients had several tumor lesions, and one patient had
a unifocal lesion. The mean tumor size of the metastatic
lesions was 5.6 cm (range 0.5 to 11.6 cm).
PET findings
Based on the visual assessment of the radiotracer
uptake (Figure 1), on a per-patient basis, there were
positive findings in 13/33 of the patients investigated
with [11C]MTO PET and in 11/33 when [11C]ACE was
used. Increased accumulation of both tracers was
observed in 9/33 of cases, while in 18/33, neither of the
tracers allowed the visualization of any of the tumors.
Table 1 shows the results of the sensitivity and specificity
analyses on a patient-per-patient basis for [11C]MTO
and [11C]ACE PET imaging of hepatic tumors. Interest-
ingly, group III, i.e., patients with types of tumors other
than HCC or FNH, was negative for both tracers.
As regard the various tumor types, in group I, [11C]MTO
detected 27/59 of the HCC lesions, 26/59 by [11C]ACE, and
both tracers detected 22/59. When both tracers were
positive, [11C]ACE detected more lesions compared to
[11C]MTO (three patients with [11C]ACE; one patient with
[11C]MTO). In group 2, [11C]MTO detected 9/18 of the
FNH lesions, 5/18 by [11C]ACE, and both detected 4/18.
The whole-body [11C]MTO PET imaging identified 14 un-
known distant metastases in four patients, while [11C]ACE
PET demonstrated 11 distant metastases in three patients,
all in the HCC patient group.
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The summary, tumor SUVmax, SUVmean, and T/L ratio
values (acquired between 35 to 40 min post-injection)
for each of the study groups are shown in Table 2.
Patients with FNH lesions (group II) had a significantly
different T/L ratio from those with miscellaneous types
of liver tumors (group III) when studied with [11C]MTO
(P = 0.002). For [11C]ACE, the T/L ratio was also signifi-
cantly different between groups I and III (P = 0.007). In
patients with HCC (group I), significant negative
correlations existed between tumor grade and SUVmax
(R2 = −0.66, P = 0.010) and SUVmean (R
2 = −0.54,
P = 0.046) for [11C]ACE.
Figure 2 shows the time-activity curves of tumors after
injection of [11C]ACE or [11C]MTO (T/L ratio versus
time after tracer injection) for HCC (Figure 2, left
panels) and FNH (Figure 2, right panels) patients.
Variability of the tracer uptake (both [11C]ACE and
[11C]MTO) in different tumors is clearly evident in HCC
and FNH.
Correlation of PET imaging with histopathological
findings in HCC lesions
Of the 14 patients with confirmed HCC, histological as-
sessment showed that one patient had a tumor highly
differentiated, nine had moderately differentiated, and
four had minimally differentiated HCCs. For highly and
moderately differentiated lesions, [11C]MTO PET im-
aging was clearly positive in six of ten patients, while
[11C]ACE PET imaging demonstrated abnormal findings
in seven of ten patients. None of the patients with poorly
differentiated lesions showed increased tumoral tracer
uptake as compared with surrounding liver activity (T/L =
0.81 ± 0.4 with [11C]MTO and T/L = 0.98 ± 0.3 with
[11C]ACE).
Discussion
In the present study, we evaluated the feasibility of two
PET tracers for the detection of HCC tumors by PET
and compared it with the detection of FNH and liver
metastases from other tumors. [11C]ACE is claimed by
other authors to have high sensitivity and specificity for
small nodules of HCC, and it is believed to reflect
increased beta-oxidation of fatty acids. We further
examined [11C]MTO based on reported findings of
GABA receptor upregulation in HCC and binding of
metomidate to GABA receptors. To our knowledge, this
is the first study of [11C]MTO in hepatic tumors.
The [11C]MTO, which previously evaluated adrenal
masses [20,21], demonstrated varying degrees of uptake
in HCC and FNH lesions (Figure 1). The sensitivity of
Figure 1 Representative transaxial MRI and PET images of patients with hepatocellular carcinoma and focal nodular hyperplasia.
Arrows indicate tumors, and arrowheads indicate normal uptake in the spleen. HCC: A 71-year-old male had three tumors; the largest tumor
(diameter, 3 cm) was biopsy-proven as a HCC grade II lesion. FNH: A 43-year-old female had biopsy-proven FNH.
Table 1 Sensitivity and specificity of [11C]MTO and [11C]ACE PET imaging of hepatic tumors based on patient-per-
patient analysis
Group Sensitivity (%) Specificity (%)
[11C]ACE [11C]MTO [11C]ACE [11C]MTO
Group I (HCC, n = 14) 50 43 79 63
Group II (FNH, n = 9) 44 78 71 75
Group III (other liver tumors, n = 10) NA NA NA NA
NA, not applicable.
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[11C]MTO for the detection of HCC and FNH was 43%
and 78%, correspondingly (Table 1). The SUVs for HCC
and FNH did not differ statistically (Table 2), and it was
not possible to differentiate between malignant or be-
nign lesions on the basis of visual assessments or SUV
measurements. Interestingly, the whole-body [11C]MTO
PET scan depicted some distant metastases of moder-
ately differentiated HCC lesions. The mechanism of
enhanced uptake in these lesions is intriguing but might
be related to the contribution of the metastatic tumor
cells to an abnormal steroidogenic pathway.
The [11C]ACE PET scan in 14 patients with HCC had
a low detection rate. This is contradictory to two previ-
ously published studies, which reported encouraging
results for the use of [11C]ACE in assessing HCC lesions
[11-13]. In their study involving patients with histo-
pathologically confirmed HCC, Li et al. found a
sensitivity of 78% (14/18) in a patient-based analysis.
Our results indicate a sensitivity of only 50% (7/14) in a
patient-based analysis (Table 1). For well to moderately
differentiated lesions, Li et al. report that [11C]ACE PET
was positive in 10 of 12 patients (83%) and revealed 28
of 33 lesions (85%). In our study, [11C]ACE PET imaging
demonstrated unexpected findings in seven of ten
patients (70%) with well to moderately differentiated
lesions and revealed 26 of the 46 lesions (57%). In
another study by Ho et al., the detection sensitivity of
[11C]ACE PET on a per-lesion basis in HCC patients is
87% (55 lesions, 32 patients). In our study, the detection
sensitivity was only 44% (59 lesions, 14 patients)
(Table 1). A possible explanation for the discrepancy be-
tween our results and the earlier findings could be the
differences in races, carcinogenesis, study designs, and
the relatively small number of HCC patients investigated
Table 2 Tumor uptake of [11C]ACE and [11C]MTO in different study groups
Group [11C]ACE [11C]MTO
SUVmax SUVmean T/L SUVmax SUVmean T/L
Group I (HCC; n = 14) 8.17 ± 3.03 5.68 ± 2.06 1.44 ± 0.75* 9.84 ± 6.36 6.43 ± 4.68 1.19 ± 0.81
Group II (FNH; n = 9) 7.36 ± 3.51 5.27 ± 2.44* 1.25 ± 0.31 12.82 ± 5.23 9.93 ± 3.61 1.51 ± 0.32*
Group III (other liver tumors; n = 10) 5.67 ± 3.16 4.21 ± 2.48 0.75 ± 0.28 7.76 ± 4.62 5.78 ± 3.90 0.75 ± 0.39
Results are expressed as mean ± SD. SUV, standardized uptake value; T/L, tumor-to-liver ratio. *P < 0.05 versus group III (unpaired t test).
Figure 2 Time-activity curves of tumors. After injection of [11C]MTO (upper A panels) and [11C]ACE (lower B panels) expressed as tumor-to-
liver ratio versus time after injection. Lines represent the mean value of individual experiments. Left panels represent hepatocellular carcinoma
(HCC) and right panels focal nodular hyperplasia (FNH).
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in our study. Notably, most of the HCC in Orientals are
caused by hepatitis B or hepatitis C virus infection,
which are somewhat different from the hepatoma caused
by alcoholism in Western people.
Approximately 30% of FNH lesions showed increased
uptake of [11C]ACE, and it was not possible to discrim-
inate FNH from HCC based on visual assessment or
differences in semi-quantitative analysis. The results of
the present study indicate that both tracers detect a vari-
able yet low percentage of lesions representing HCC and
FNH. No liver metastases of other primary tumors were
detected with these tracers. However, due to the limited
cases and limited kinds of cancers, i.e., only six liver me-
tastases and four metastases of colon cancer, this might
not be conclusive. The fact that liver metastases of colo-
rectal cancer do not take up lipid PET tracers has
already been published [11]. In contrast, should this
group be larger, uptake would be expected in metastases
from prostate cancers and some others (lung, breast).
Although CT modalities can characterize most liver
lesions, MRI has emerged as the best imaging test for the
detection and characterization of liver lesions. MRI is
considered superior due to its high lesion-to-liver contrast
and high spatial resolution, and furthermore, it does not use
ionizing radiation [24]. [18F]FDG PET has become an
established tool in the evaluation of metastatic liver disease.
However, [18F]FDG PET has not been proven very useful for
the evaluation of HCC. Several studies have revealed that the
sensitivity of [18F]FDG PET in the diagnosis of HCC is ap-
proximately 50% [25,26]. Although other positron-emitting
tracers ([11C]ACE, [11C]choline, [18F]fluorocholine, and
[18F]fluorodeoxygalactose) have been evaluated for diagnosis
of HCC as well, none of them succeeds fully alone
[11-13,17,18,27]. For example, [11C]choline has the same
pitfalls but somewhat better sensitivity values. However,
[18F]fluorocholine has been registered in several EU coun-
tries in this indication, and the dual-tracer PET/CT (i.e.,
[18F]FDG and [11C]ACE or [18F]FDG and [18F]fluorocholine)
has shown good results for HCC detection and staging
[18,19].
Limitations
It is internationally agreed that the medical challenge is
to detect HCC in the early phase when tumors are less
than 2 cm because then treatment can be curative. In
this study population, the HCC tumor sizes ranged from
3 to 19 cm in diameter, as determined by MRI. This is
reasonable for the purpose of testing the feasibility of
the two tracers, but lacks any evidence for the detection
of smaller tumors. The number of patients included in
this study (14 HCC, 9 FNH, and 10 other hepatic
tumors) is limited, which can be regarded as a study
limitation. Accordingly, the results of sensitivity and spe-
cificity should be considered as approximates.
The most intensive liver hotspots were used for the
PET analysis. Unfortunately, these lesions were not al-
ways the same as those that were biopsied. We recognize
that due to tumor heterogeneity, the observed SUV
values do not necessarily represent the histological
samples. Patients are treated according to histological
findings, and it is not possible to take biopsies from all
the liver lesions.
Conclusions
None of the secondary liver metastases were PET-
positive for any of the two tracers. None of the tracers,
however, reached a level of sensitivity for detection of
hepatic tumors that would support their appropriateness
as diagnostic PET tracers for HCC.
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